You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight
management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section
5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* or, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight
management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section
5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* or, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1
Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1
Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* and, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight
management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section
5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* or, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight
management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of, =30 kg/m2 (obesity), or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section
5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:, obesity* or, body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI = 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
